The Life Insurance Market
The government's drugs advisory body actually helps many more people ward off the need to claim on their critical illness insurance than they're given credit for, new research reveals.
A study by the Financial Times found that the National Institute for Health and Clinical Excellence (NICE) has actually approved the use of three-quarters (73 per cent) of the cancer medicines it has looked at since 2002.
Taking a wider look at all the drugs scrutinised, the approval figure goes up to more than eight-in-ten (83 per cent).
The research comes after NICE faced new criticism after indicating that the limited evidence of cancer drug Avastin's "modest benefit" was "highly uncertain".
However, it's hoped that the new research will reassure people with critical illness insurance that NICE is helping them live healthier lives more often than not.
Post your own comment